Finally, miR-25 has been reported to stimulate growth and invasion of ovarian cancer cells by targeting key tumor-suppressors, including LATS2 and BIM [56, 57], while miR-25 overexpression in ovarian cancer patients has been associated with adverse disease outcome [58]. Here, BCL2L11 is linked to ovarian cancer.